地西他滨对骨髓增生异常综合征患者血浆中P15基因启动子区域甲基化的影响

Changes of P15 gene promoter region methylation following decitabine treatment in the plasma of patients with myelodysplastic syndromes

目的:检测骨髓增生异常综合征(MDS)患者血浆中P15基因启动子区域甲基化状况及地西他滨对其甲基化的影响。方法:采用甲基化特异性聚合酶链反应(methylation-specific PCR,MSP)法检测1例初治的MDS患者、3例MDS转化而来的AML患者使用地西他滨序贯半量CAG方案治疗前后血浆中P15基因启动子区域CPG岛甲基化情况,并分析其临床疗效。结果:4例患者治疗前均有P15基因甲基化,治疗1疗程后有3例患者P15基因甲基化得到逆转,4例患者中有2例获得临床缓解,2例无效。结论:MDS的发生与P15基因甲基化相关,地西他滨对MDS患者血浆P15基因高甲基化具有明显的去甲基化作用。P15基因甲基化检测可能成为MDS辅助诊断和预后判断的分子标记。

Objective：To detect the methylation status of P15 gene promoter region in the plasma of patients with myelodysplastic syndrome（MDS）,and to investigate the demethylating effects of dicitabine.Method：Methylation-specific PCR（MSP） was used to detect the methylation status of P15 gene promoter region in the plasma of 4 patients,among them,one newly diagnosed MDS,three progressed into acute leukemia,with myelodysplastic syndrome before and after treated with decitabine plus semis CAG therapy.Result：Four cases were found to have an increased methylation in the promoter region,after treated with decitabine plus semis CAG,3 cases were not found increased methylation.In 4 cases,2 cases gain clinical response,and the other 2 cases were useless.Conclusion：P15 gene hypermethylation is associated with MDS pathogenesis.Decitabine has demethylating effect on the plasma from MDS patients The methylation status of P15 gene may serve as an important molecular marker to provide evidence for MDS diagnosis and predict the prognosis.